STShin Takayama

Shin Takayama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shin Takayama has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and Effectiveness of an Integrative Treatment of Acupuncture-Based Intervention in Survivors of Breast Cancer With Postmastectomy Pain Syndrome: Protocol for a Single-Center, Single-Arm Exploratory Trial

    by Naruaki Kawasaki, Hiroto Ishiki, Naho Matsubara, Takako Ikegami, Ayaka Ishikawa, Sayaka Arakawa, Asuka Takahashi, Tomoko Uchida, Yukie Nameki, Yoko Horiguchi, et al.

    Background: Postmastectomy pain syndrome (PMPS) is a prevalent chronic pain condition that occurs after breast cancer surgery, often impairing quality of life in survivors of breast cancer. Despite its prevalence, no standardized treatment has been established. Acupuncture has been reported to be an efficacious intervention for the management of chronic pain and may be an effective treatment for PMPS. Objective: This study aims to explore the effectiveness and safety of integrative treatment of acupuncture-based intervention for PMPS. Methods: This is a single-center, single-arm, prospective interventional study. Eligible participants are patients with breast cancer who experience chronic postoperative pain in the chest, neck, or shoulder with a numerical rating scale (NRS) score ≥4, are at least 6 months postcurative treatment, have no evidence of disease recurrence, and are not receiving anticancer treatment at enrollment. Participants will receive the intervention once weekly for 12 sessions, followed by a 4-week observation period. The primary end point is the change in the average pain NRS score from baseline to week 16. Results: The study commenced in October 2023 and is scheduled to continue through March 31, 2027. The first participant was enrolled on October 24, 2023. As of the manuscript submission, 24 patients have been enrolled. Conclusions: This study will explore the potential role of an integrative treatment of acupuncture-based intervention in the management of PMPS. The results will contribute to the evidence base for acupuncture in PMPS and inform the design of future clinical studies.

  • Open Access

    Randomized Controlled Trial to Relieve Pain of Chemotherapy-Induced Peripheral Neuropathy by Magnetic Field: SMILE Study

    by Emi Kubo, Eriko Satomi, Toru Mukohara, Nozomu Fuse, Masashi Wakabayashi, Yuichiro Tsukada, Hiroto Ishiki, Shin Takayama, Yukihide Kanemitsu, Iwao Kishita, et al.

    Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of taxanes and platinum-based agents, impairing quality of life. Duloxetine is the only drug with proven efficacy, but is often limited by tolerability. AT-04 is a portable alternating magnetic field device that activates descending pain modulatory systems and has shown safety in other pain settings. This investigator-initiated trial evaluated the efficacy and safety of AT-04 for persistent CIPN. Methods: We conducted a randomized, double-blind, sham-controlled, multicenter phase II study. Patients with CIPN lasting ≥12 weeks after chemotherapy and pain NRS ≥ 4 were enrolled. Participants used AT-04 or sham devices twice daily for 12 weeks. The primary endpoint was the change in pain NRS on day 85. Secondary endpoints included tingling NRS, numbness NRS, CIPN20 subscales, and safety. Results: Twenty-eight patients were randomized (14 per arm). No significant difference was observed in pain NRS on day 85 {AT-04: −1.74 ± 0.6 vs. sham device: −1.45 ± 0.6; one-sided p = 0.36, effect size (ES) = 0.48}. CIPN20 motor scores improved with AT-04 on days 29 (−9.82 ± 13.8 vs. 0.74 ± 8.7, respectively; p = 0.035, ES = 0.92) and 57 (−11.81 ± 10.6 vs. −0.54 ± 6.7, respectively; p < 0.01, ES = 1.26). Among patients whose last chemotherapy had ended >1 year earlier (n = 16), motor scores improved from days 29 (−12.43 ± 10.3 vs. 2.38 ± 8.9, respectively; p < 0.01, ES = 1.55) to 85 (−11.76 ± 10.1 vs. −0.07 ± 11.5, respectively; p = 0.049, ES = 1.08), while sensory/autonomic scales showed trends. No treatment-related adverse events occurred in the AT-04 group. Conclusions: AT-04 did not significantly reduce pain NRS but improved motor function in CIPN patients, especially in those >1 year after chemotherapy. AT-04 may be a promising non-pharmacological option; larger confirmatory trials are required.

  • Emerging advances in non-surgical ablation for early-stage breast cancer

    by Shin Takayama, Takeshi Murata, Chikashi Watase, Hinako Maeda, Ayako Nakashoji, Ayumi Ogawa, Mengge Chen, Natsuko Ogi, Takayuki Kinoshita

    Recent advances in diagnostic imaging have led to an increase in the detection of early-stage breast cancer, prompting growing interest in minimally invasive breast surgery. These approaches include the omission of axillary lymph node dissection, use of endoscopic or robot-assisted surgery, and application of non-surgical ablation techniques. Non-surgical ablation therapy aims to eradicate tumor tissue in situ by delivering localized thermal or cryogenic energy under imaging guidance without surgical resection. Among these, radiofrequency ablation (RFA) and cryoablation have been the most extensively studied, showing promising results for small early-stage tumors. Clinical studies have reported high rates of complete tumor ablation, favorable safety profiles, and excellent cosmetic outcomes. Moreover, single-arm prospective trials have provided 5-year follow-up data, offering valuable insights into long-term efficacy. Despite these encouraging results, non-surgical ablation has not been internationally adopted as a standard treatment because of concerns regarding oncological surveillance and outcome validation. However, in Japan, RFA for early-stage breast cancer was approved for insurance coverage in December 2023. This review summarizes the current trends and clinical evidence for RFA and cryoablation, and discusses the regulatory pathways required for RFA insurance approval in Japan.


  • Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies

    by Aya Imai, Ryo Tsunashima, Yu Hidaka, Sae Kitano, Chikage Kato, Akira Watanabe, Midori Morita, Koichi Sakaguchi, Yoshiaki Sota, Masahiko Suzuki, et al.

    Background In recent years, multigene assays have become indispensable tools for predicting the recurrence risk of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and guiding adjuvant chemotherapy decisions. Curebest™ 95GC Breast (95GC), developed in 2011 as a domestically produced multigene assay for postoperative recurrence prediction, has been commercially available since 2013. Since 2021, five validation studies evaluating the predictive performance 95GC have been published. This study presents an integrated analysis of these studies to validate the prognostic utility of 95GC further. Methods The integrated analysis included 719 real-world cases of luminal-type node-negative breast cancer patients who underwent adjuvant hormone therapy alone without extended endocrine treatment. In addition, an expanded cohort incorporating 294 cases from Western patients within the GEO public database was analyzed, resulting in a total of 1013 cases. Results Among the 719 real-world cases, 550 (76.5%) were classified into the 95GC Low-risk group, demonstrating a significantly superior prognosis compared to the High-risk group (P < 1.00e−12). The 5-year distant recurrence-free survival (DRFS) rate in the Low-risk group was approximately 98%, with consistent findings observed in the expanded cohort. Furthermore, an analysis of 754 CEL files using 21GC (a proxy for Oncotype DX®) identified 318 cases (42.2%) as the 21GC intermediate risk. 95GC successfully stratified these cases into two prognostically distinct subgroups. Conclusions These findings underscore the clinical utility of 95GC in safely omitting chemotherapy for Low-risk patients with good prognosis and in further stratifying the 21GC Intermediate-risk cases, thereby contributing to personalized treatment strategies.


  • Open Access

    Data from Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ

    by Momoko Tokura, Jun Nakayama, Marta Prieto-Vila, Sho Shiino, Masayuki Yoshida, Tomofumi Yamamoto, Naoaki Watanabe, Shin Takayama, Yutaka Suzuki, Koji Okamoto, et al.

    Ductal carcinoma in situ (DCIS) is a precursor to invasive breast cancer. The frequency of DCIS is increasing because of routine mammography; however, the biological features and intratumoral heterogeneity of DCIS remain obscure. To address this deficiency, we performed single-cell transcriptomic profiling of DCIS and invasive ductal carcinoma (IDC). DCIS was found to be composed of several transcriptionally distinct subpopulations of cancer cells with specific functions. Several transcripts, including long noncoding RNAs, were highly expressed in IDC compared with DCIS and might be related to the invasive phenotype. Closeness centrality analysis revealed extensive heterogeneity in DCIS, and the prediction model for cell-to-cell interactions implied that the interaction network among luminal cells and immune cells in DCIS was comparable with that in IDC. In addition, transcriptomic profiling of HER2+ luminal DCIS indicated HER2 genomic amplification at the DCIS stage. These data provide novel insight into the intratumoral heterogeneity and molecular features of DCIS, which exhibit properties similar to IDC.Significance:Investigation of the molecular features of ductal carcinoma in situ at single cell resolution provides new insights into breast cancer biology and identifies candidate therapeutic targets and diagnostic biomarkers.

  • Open Access

    Supplementary Data from Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ

    by Momoko Tokura, Jun Nakayama, Marta Prieto-Vila, Sho Shiino, Masayuki Yoshida, Tomofumi Yamamoto, Naoaki Watanabe, Shin Takayama, Yutaka Suzuki, Koji Okamoto, et al.

    Supplementary Data from Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ

  • Open Access

    Supplementary Figure from Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ

    by Momoko Tokura, Jun Nakayama, Marta Prieto-Vila, Sho Shiino, Masayuki Yoshida, Tomofumi Yamamoto, Naoaki Watanabe, Shin Takayama, Yutaka Suzuki, Koji Okamoto, et al.

    Supplementary Figure from Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ

  • Open Access

    Supplementary Data from Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ

    by Momoko Tokura, Jun Nakayama, Marta Prieto-Vila, Sho Shiino, Masayuki Yoshida, Tomofumi Yamamoto, Naoaki Watanabe, Shin Takayama, Yutaka Suzuki, Koji Okamoto, et al.

    Supplementary Data from Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ

  • Open Access

    Data from Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ

    by Momoko Tokura, Jun Nakayama, Marta Prieto-Vila, Sho Shiino, Masayuki Yoshida, Tomofumi Yamamoto, Naoaki Watanabe, Shin Takayama, Yutaka Suzuki, Koji Okamoto, et al.

    Ductal carcinoma in situ (DCIS) is a precursor to invasive breast cancer. The frequency of DCIS is increasing because of routine mammography; however, the biological features and intratumoral heterogeneity of DCIS remain obscure. To address this deficiency, we performed single-cell transcriptomic profiling of DCIS and invasive ductal carcinoma (IDC). DCIS was found to be composed of several transcriptionally distinct subpopulations of cancer cells with specific functions. Several transcripts, including long noncoding RNAs, were highly expressed in IDC compared with DCIS and might be related to the invasive phenotype. Closeness centrality analysis revealed extensive heterogeneity in DCIS, and the prediction model for cell-to-cell interactions implied that the interaction network among luminal cells and immune cells in DCIS was comparable with that in IDC. In addition, transcriptomic profiling of HER2+ luminal DCIS indicated HER2 genomic amplification at the DCIS stage. These data provide novel insight into the intratumoral heterogeneity and molecular features of DCIS, which exhibit properties similar to IDC.Significance:Investigation of the molecular features of ductal carcinoma in situ at single cell resolution provides new insights into breast cancer biology and identifies candidate therapeutic targets and diagnostic biomarkers.